Kamel Laribi

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 441 citations

Medicine, Oncology, Pharmacotherapy +9

Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Philippe Moreau, Michel Attal, Denis Caillot et al. · Journal of Clinical Oncology · 2017 · 320 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Management and outcome of primary CNS lymphoma in the modern era

Caroline Houillier, Carole Soussain, Hervé Ghesquières et al. · Neurology · 2020 · 245 citations · Full text

Medicine, Oncology, Chemotherapy +12

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié et al. · Blood · 2016 · 235 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12